Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Several grapefruit/juice and timing/amount/quantification claims are either unsupported or conflict with the label’s interaction threshold; multiple additional claims about citrus safety and “FDA labels warn against grapefruit use” are not supported as stated. Some dosing/admin statements are supported.
Category Scores
Accurate Statements
Grapefruit inhibits CYP3A4 and can increase atorvastatin plasma concentrations.
Section 7.2 Grapefruit Juice: contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Grapefruit juice interferes with Lipitor (i.e., affects atorvastatin exposure).
Section 7.2 Grapefruit Juice: can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption.
Lipitor can be administered as a single dose at any time of the day, with or without food.
Section 2.1: 'LIPITOR can be administered as a single dose at any time of the day, with or without food.'
Dose (10-80 mg) can influence interactions with other substances.
Section 7.1: for strong CYP3A4 inhibitors (clarithromycin, protease inhibitors, itraconazole) 'caution should be used when the LIPITOR dose exceeds 20 mg'; Section 2.1 provides dose range 10-80 mg once daily.
Unsupported Statements
Lipitor (atorvastatin) has no known interactions with oranges or orange juice.
Label excerpt provided contains no statement about oranges/orange juice interactions being absent.
Oranges do not contain the furanocoumarins responsible for grapefruit’s CYP3A4 inhibition.
No such compositional claim is present in the provided label excerpts.
Standard orange juice is safe with Lipitor.
No label statement provided addresses orange juice safety with atorvastatin.
A study tested 8 ounces daily for a week in healthy volunteers on lovastatin and found no pharmacokinetic changes.
Not supported by the provided LIPITOR label excerpts (no such study details provided).
The same logic applies to atorvastatin due to similar metabolism.
The label excerpts do not provide a basis for generalizing from lovastatin to atorvastatin.
Seville oranges contain trace furanocoumarins similar to grapefruit.
No such claim appears in the provided label excerpts.
Avoiding Seville oranges is recommended because of their furanocoumarin content.
No label recommendation regarding Seville oranges.
Even 200-250 mL of grapefruit juice once daily boosts atorvastatin exposure by over 100% in many patients.
The label excerpt specifies 'especially with excessive grapefruit juice consumption (>1.2 liters per day)' but does not provide a 200–250 mL quantitative increase.
Whole grapefruit has a comparable effect on atorvastatin exposure.
The provided label excerpt only addresses grapefruit juice.
FDA labels warn against grapefruit use for Lipitor.
Section 7.2 describes increased concentrations 'especially' with excessive consumption; no 'avoid grapefruit use' wording is present in the provided label excerpt.
Oranges, orange juice, lemons, and limes are safe with statin users.
No such claims about lemons/limes or general citrus safety are supported by the provided label excerpts.
Tangerines and mandarins are safe with statin users.
No such claims about these citrus fruits are supported by the provided label excerpts.
Grapefruit, pomelos, and some tangelos should be avoided with Lipitor.
The label excerpt provided addresses grapefruit juice; it does not mention pomelos or tangelos or an explicit 'should be avoided' instruction.
If unavoidable, separate grapefruit products from Lipitor by at least 72 hours.
No label excerpt provided supports a 72-hour separation instruction.
Even small amounts of grapefruit juice (one glass) can elevate atorvastatin levels by 3-10 times and this effect can last up to 24 hours.
The provided label excerpt does not provide such magnitude ('3-10 times') or duration ('up to 24 hours').
Grapefruit use with Lipitor can potentially increase side effect risks such as muscle pain or rhabdomyolysis.
The label excerpts provided discuss skeletal muscle effects for LIPITOR and increased myopathy risk with certain interacting drugs, but do not explicitly tie grapefruit consumption to muscle pain/rhabdomyolysis in the provided text.
Consistency in taking Lipitor matters.
Label excerpts provided do not include adherence/consistency counseling.
Dose (10-80 mg) and liver function can influence interactions between Lipitor and other substances.
While dose thresholds for certain interacting drugs are label-supported, the provided excerpts do not state that 'liver function' specifically influences drug-drug interaction magnitude.
Contradictions
Low
AI Statement
Even small amounts of grapefruit juice (one glass) can elevate atorvastatin levels by 3-10 times and this effect can last up to 24 hours.
Label Reference
Section 7.2 Grapefruit Juice: increased concentrations 'especially with excessive grapefruit juice consumption (>1.2 liters per day)'.
Important Omissions
Label-supported interaction threshold: grapefruit juice effect is described as 'especially with excessive grapefruit juice consumption (>1.2 liters per day)'.
Importance:
Moderate
Label-supported clarification that grapefruit interaction details are specific to grapefruit juice and components inhibiting CYP3A4, without listing other citrus fruits.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response overstates quantified grapefruit effects at small amounts and adds unsupported/incorrect dietary guidance (other citrus fruits, pomelos/tangelos, and 72-hour separation). While it correctly notes CYP3A4 inhibition and increased atorvastatin concentrations from grapefruit juice, the unsupported magnitude and additional restrictions could mislead safe use relative to the label’s described context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Major portions of the grapefruit/orange interaction guidance include unsupported quantitative claims and additional citrus-specific avoidance/scheduling not supported by the provided label excerpts.
Suggested Improvement
Restrict grapefruit interaction statements to Section 7.2 wording (CYP3A4 inhibition and increased atorvastatin concentrations, especially with >1.2 L/day grapefruit juice) and remove/specifically qualify claims about oranges/lemons/limes/tangerines/mandarins/seville oranges/pome/grapefruit whole fruit, and any 72-hour separation or quantified (3–10x, up to 24h, >100% at 200–250 mL) estimates not present in the label excerpt.